How GLP-1–Based Therapies Work
GLP-1–based medications, including tirzepatide, act on hormonal pathways involved in appetite regulation and glucose metabolism. Tirzepatide interacts with both GLP-1 and GIP receptors, two incretin hormones that help regulate the body’s response to food intake.
These pathways are involved in signaling fullness, influencing insulin and glucagon activity, and supporting post-meal blood-sugar regulation. By acting on these receptors, GLP-1–based therapies may influence appetite-related signaling and digestive processes in some individuals. The degree of these effects varies and represents only one component of a broader, medically supervised wellness approach that may also include nutrition guidance, physical activity, and behavioral support.
Individual responses differ, and no specific changes in appetite, weight, or metabolic outcomes can be guaranteed.
